News & Updates

IGT Chairman Erik Paulsen Joins Healthy Future Task Force Treatments Subcommittee Roundtable

A Troubling Policy Proposal

Prioritizing Minority Health

IGT Statement on the Introduction of the Medicaid VBPs for Patients Act (H.R. 7389)

Rare Disease Day Spotlight: Hope for HPP Patients

Changing the Way We Look at Huntington’s Disease

IGT Statement on CMS Final Rule on Medicaid Value-based Purchasing Arrangements

IGT Statement on Senate's FY2022 Appropriations Bill

Patient Perspective: Khrystal Davis

IGT Statement on ICER’s Analysis of the Accelerated Approval Pathway

The Importance of National Minority Health Month

NEW IGT Policy Resources Available

IGT Recognizes Rare Disease Day

IGT Comments on CMS Final Rule on Value-based Purchasing Arrangements

Patient Perspective: Erin Frey with CureDuchenne

Patient Perspective: Cure SMA

Dr. Peter Marks Clarifies FDA’s Approach to Gene Therapies After CRL for Hemophilia A Treatment

Patient Perspective: EveryLife Foundation for Rare Diseases

IGT Comments on CMS Proposed Rule on Value-based Purchasing Arrangements

IGT Webinar on CMS Proposed Rule on Value-based Purchasing

IGT to Host Webinar on CMS Proposed Rule on Value-based Purchasing

IGT Statement on CMS Proposed Rule to Facilitate Value-based Purchasing Arrangements

Patient Perspective: Susan Ruediger

IGT Joins Axios to Host Webinar on Medical Research During a Crisis

FDA’s Dr. Peter Marks on Ways to Preserve Ongoing Medical Research During the Pandemic

Patient Perspective: Seth Rotberg

NEW INSTITUTE LAUNCHED TO ENSURE THE U.S. HEALTHCARE SYSTEM IS READY FOR GENE THERAPIES

Manufacturing: the next breakthrough in gene therapy

FDA News Release: FDA Continues Strong Support of Innovation in Development of Gene Therapy Products

Progress in Gene Therapy Needs to Be Accelerated